Диссертация (1174200), страница 49
Текст из файла (страница 49)
– № 14. – P. 1630-1636.131. Eifler A.C. Optional or permanent: clinical factors that optimize inferior vena cavafilter utilization / A.C. Eifler [et al.] // Journal of Vascular and InterventionalRadiology. – 2013. – Т. 24. – № 1. – P. 35-40.132. Eklof B. The temporary arteriovenous fistula in venous reconstructive surgery. / B.Eklof [et al.] // International angiology: a journal of the International Union ofAngiology. – 1985. – Т. 4. – № 4. – P. 455-462.133. Eklof B. Indications for surgical treatment of iliofemoral vein thrombosis / B.Eklof [et al.] // Hematology/Oncology Clinics of North America. – 2000.
– Т. 14. –№ 2. – P. 471-482.134. Eklof B. Role of thrombectomy and temporary arteriovenous fistula in acuteiliofemoral venous thrombosis / B. Eklof, E. Einarsson, G. Plate // Surgery of theVeins. – Grune & Stratton Orlando (Florida), 1985. – P. 131-145.135.
Es N. van. Direct oral anticoagulants compared with vitamin K antagonists foracute venous thromboembolism: evidence from phase 3 trials / N. van Es [et al.] //Blood. – 2014. – Т. 124. – № 12. – P. 1968-1975.299136. Faghihi Langroudi T. The Association between the Pulmonary Arterial ObstructionIndex and Atrial Size in Patients with Acute Pulmonary Embolism / T. FaghihiLangroudi [et al.] // Radiology Research and Practice. – 2019.
– P. 1-6.137. Falck-Ytter Y. Prevention of VTE in orthopedic surgery patients: antithrombotictherapy and prevention of thrombosis: American College of Chest Physiciansevidence-based clinical practice guidelines / Y. Falck-Ytter [et al.] // Chest. –2012. – Т. 141. – № 2. – P. 278S-325S.138. Farge D. International clinical practice guidelines for the treatment and prophylaxisof venous thromboembolism in patients with cancer / D. Farge [et al.] // Journal ofThrombosis and Haemostasis. – 2013.
– Т. 11. – № 1. – P. 56-70.139. Fowler R.A. Cost-effectiveness of dalteparin vs unfractionated heparin for theprevention of venous thromboembolism in critically ill patients / R.A. Fowler [etal.] // Jama. – 2014. – Т. 312. – № 20. – P. 2135-2145.140. Gall H. An epidemiological analysis of the burden of chronic thromboembolicpulmonary hypertension in the USA, Europe and Japan / H. Gall [et al.] //European Respiratory Review. – 2017.
– Т. 26. – № 143. – P. 1-10.141. Garcia-Godoy F. Retrieval of inferior vena cava filters after prolonged indwellingtime / F. Garcia-Godoy [et al.] // Archives of internal medicine. – 2011. – Т. 171. –№ 21. – 7. P. 1953-1956.142. Geerts W.H. Prevention of venous thromboembolism: the Seventh ACCPConference on Antithrombotic and Thrombolytic Therapy / W.H.
Geerts [et al.] //Chest. – 2004. – Т. 126. – № 3. – P. 338S-400S.143. Gill J.R. The medicolegal evaluation of fatal pulmonary thromboembolism / J.R.Gill // Forensic pathology reviews. – Springer. – 2005. – P. 285-302.144. Glocker R.J. Bedside inferior vena cava filter placement by intravascularultrasound in critically ill patients is safe and effective for an extended time / R.J.Glocker [et al.] // Journal of Vascular Surgery: Venous and Lymphatic Disorders.
–2014. – Т. 2. – № 4. – P. 377-382.300145. Goldhaber S.Z. Venous thromboembolism: epidemiology and magnitude of theproblem / S.Z. Goldhaber // Best practice & research Clinical haematology. –2012. – Т. 25. – № 3. – P. 235-242.146. Goldhaber S.Z. Pulmonary embolism and deep vein thrombosis / S.Z. Goldhaber,H. Bounameaux // The Lancet. – 2012. – Т. 379. – № 9828. – P. 1835-1846.147.
Goldhaber S.Z. Acute pulmonary embolism: clinical outcomes in the InternationalCooperative Pulmonary Embolism Registry (ICOPER) / S.Z. Goldhaber, L. Visani,M. De Rosa // The Lancet. – 1999. – Т. 353. – № 9162. – P. 1386-1389.148. Golpe R. Long-term outcome of patients with persistent vascular obstruction oncomputed tomography pulmonary angiography 6 months after acute pulmonaryembolism / R. Golpe [et al.] // Acta Radiologica.
– 2012. – Т. 53. – № 7. – P. 728731.149. Gould M.K. Low-molecular-weight heparins compared with unfractionatedheparin for treatment of acute deep venous thrombosis: a cost-effectivenessanalysis / M.K. Gould [et al.] // Annals of internal medicine. – 1999. – Т. 130.
–№ 10. – P. 789-799.150. Grande W.J. Experience with the recovery filter as a retrievable inferior vena cavafilter / W.J. Grande [et al.] // Journal of vascular and interventional radiology. –2005. – Т. 16. – № 9. – P. 1189-1193.151. Group B.T.S.S. of C.C.P.E.G.D. British Thoracic Society guidelines for themanagement of suspected acute pulmonary embolism. / B.T.S.S. of C.C.P.E.G.D.Group // Thorax. – 2003.
– Т. 58. – № 6. – P. 470-483.152. Group P.S. Eight-year follow-up of patients with permanent vena cava filters in theprevention of pulmonary embolism: the PREPIC (Prevention du Risque d’EmboliePulmonaire par Interruption Cave) randomized study / P.S. Group // Circulation. –2005. – Т. 112.
– № 3. – P. 416-422.153. Guerreiro I. Long term prognosis of acute pulmonary embolism / I. Guerreiro [etal.] // European journal of internal medicine. – 2019. – № 67. – P. 84-88.154. Guyatt G.H. Executive summary: antithrombotic therapy and prevention ofthrombosis: American College of Chest Physicians evidence-based clinical301practice guidelines / G.H. Guyatt [et al.] // Chest. – 2012.
– Т. 141. – № 2 Suppl. –P. 53S-70S.155. Hajduk B. Vena cava filter occlusion and venous thromboembolism risk inpersistently anticoagulated patients: a prospective, observational cohort study / B.Hajduk [et al.] // Chest. – 2010. – Т. 137. – № 4. – P. 877-882.156. Haley M.W. Bedside insertion of inferior vena cava filters by a medical intensivist:preliminary results / M.W. Haley, A.B. Christmas, R.F. Sing // Journal of intensivecare medicine. – 2009. – Т.
24. – № 2. – P. 144-147.157. Hammond C.J. Audit of the use of IVC filters in the UK: experience from threecentres over 12 years / C.J. Hammond [et al.] // Clinical radiology. – 2009. – Т. 64.– № 5. – P. 502-510.158. Hann C.L. The role of vena caval filters in the management of venousthromboembolism / C.L. Hann, M.B. Streiff // Blood reviews. – 2005. – Т.
19. –№ 4. – P. 179-202.159. Haut E.R. The effectiveness of prophylactic inferior vena cava filters in traumapatients: a systematic review and meta-analysis / E.R. Haut [et al.] // JAMAsurgery. – 2014. – Т. 149. – № 2. – P. 194-202.160. Heit J.A. Predictors of survival after deep vein thrombosis and pulmonaryembolism: a population-based, cohort study / J.A. Heit [et al.] // Archives ofinternal medicine.
– 1999. – Т. 159. – № 5. – P. 445-453.161. Heit J.A. Predictors of recurrence after deep vein thrombosis and pulmonaryembolism: a population-based cohort study / J.A. Heit [et al.] // Archives ofinternal medicine. – 2000. – Т. 160. – № 6. – P. 761-768.162.
Heit J.A. Estimated annual number of incident and recurrent, non-fatal and fatalvenous thromboembolism (VTE) events in the US. / J.A. Heit, A.T. Cohen, F.A.Anderson // Am Soc Hematology. – 2005. – 106(11). – 910 p.163. Hemmila M.R. Prophylactic inferior vena cava filter placement does not result in asurvival benefit for trauma patients / M.R. Hemmila [et al.] // Annals of surgery. –2015.
– Т. 262. – № 4. – P. 577-585.302164. Hirsh J. Heparin / J. Hirsh // New England Journal of Medicine. – 1991. – Т. 324.– № 22. – P. 1565-1574.165. Hirsh J. Parenteral anticoagulants: American College of Chest Physiciansevidence-based clinical practice guidelines / J. Hirsh [et al.] // Chest. – 2008. –Т. 133. – № 6. – P. 141S-159S.166. Hodgkiss-Harlow K. Technical factors affecting the accuracy of bedside IVC filterplacement using intravascular ultrasound / K. Hodgkiss-Harlow [et al.] // Vascularand endovascular surgery. – 2012. – Т. 46. – № 4.
– P. 293-299.167. Holbrook A. Evidence-based management of anticoagulant therapy: antithrombotictherapy and prevention of thrombosis: American College of Chest Physiciansevidence-based clinical practice guidelines / A. Holbrook [et al.] // Chest. – 2012. –Т. 141. – № 2. – P. 152S-184S.168. Holly B.P. Inferior Vena Cava Filters: Why, Who, and for How Long? / B.P.Holly, B. Funaki, M.L. Lessne // Clinics in chest medicine. – 2018. – Т. 39. – № 3.– P. 645-650.169. Holm H.A. Heparin treatment of deep venous thrombosis in 280 patients:symptoms related to dosage / H.A. Holm [et al.] // Acta Medica Scandinavica. –1984.
– Т. 215. – № 1. – P. 47-53.170. Holmer E. The molecular-weight dependence of the rate-enhancing effect ofheparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIaand kallikrein by antithrombin / E. Holmer, K. Kurachi, G.
Söderström //Biochemical Journal. – 1981. – Т. 193. – № 2. – P. 395-400.171. Huang S.Y. Safety and efficacy of an absorbable filter in the inferior vena cava toprevent pulmonary embolism in swine / S.Y. Huang [et al.] // Radiology. – 2017. –Т. 285. – № 3. – P. 820-829.172. Hull R.D. Optimal therapeutic level of heparin therapy in patients with venousthrombosis / R.D. Hull [et al.] // Archives of Internal Medicine. – 1992.
– Т. 152. –№ 8. – P. 1589-1595.303173. Hull R.D. Subcutaneous low-molecular-weight heparin compared with continuousintravenous heparin in the treatment of proximal-vein thrombosis / R.D. Hull [etal.] // New England Journal of Medicine. – 1992. – Т. 326. – № 15. – P. 975-982.174. Hull R.D. The importance of initial heparin treatment on long-term clinicaloutcomes of antithrombotic therapy: the emerging theme of delayed recurrence /R.D. Hull [et al.] // Archives of internal medicine.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
